Tag: tazarotene

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

| December 1, 2019

J Clin Aesthet Dermatol. 2019;12(12):28–34 by Corinna E. Psomadakis, MBBS, and George Han, MD Drs. Psomadakis and Han are with the Department of Dermatology, Mount Sinai Medical Center in New York, New York. FUNDING: No funding was provided for this study. DISCLOSURES: Dr. Han has consulted for Regeneron, Sanofi Genzyme, Pfizer, Sun, and Janssen. Dr. […]

Continue Reading

Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short-Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1%

Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short-Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1%

| September 1, 2019

by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD […]

Continue Reading

Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study

Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study

| May 1, 2019

 J Clin Aesthet Dermatol. 2019;12(5)40–45 by Brandon Kirsch, MD; Paul M. Hoesly, MD; Anokhi Jambusaria, MD, MSCE; Michael G. Heckman, MS; Nancy N. Diehl, MS; and Jason C. Sluzevich, MD Drs. Kirsch (at the time of this study), Hoesly (at the time of this study), and Sluzevich are with the Department of Dermatology at the […]

Continue Reading

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential

| January 1, 2019

 J Clin Aesthet Dermatol. 2019;12(1):11–15 by James Q. Del Rosso, DO; Leon Kircik, MD; Tina Lin PharmD; and Radhakrishnan Pillai, PhD Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada. Dr. Kircik is with the Indiana University School of Medicine in Indianapolis, Indiana; Physicians Skin Care, PLLC in Louisville, Kentucky; and […]

Continue Reading

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

| November 1, 2018

 J Clin Aesthet Dermatol. 2018;11(11):15–19 by Neal D. Bhatia, MD; David M. Pariser, MD; Leon Kircik, MD; Tina Lin, PharmD; Susan Harris, MS; Lindsey Mathew; and Radhakrishnan Pillai, PhD Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Pariser is with Virginia Clinical Research, Inc. in Norfolk, Vriginia. Dr. Kircik is with […]

Continue Reading